Nanox announces agreement with CureMetrix for AI-based assistive diagnostic tool to support Nanox cloud platform

Bidding open for ZRG Medical Auctions - Bid Now - Closes Dec 11th

Nanox announces agreement with CureMetrix for AI-based assistive diagnostic tool to support Nanox cloud platform

Press releases may be edited for formatting or style | March 24, 2020 Artificial Intelligence Health IT
NANO-X IMAGING LTD ("Nanox" or the "Company"), an innovative medical imaging company, announces its collaboration with CureMetrix®, a global healthcare technology company that develops AI-driven software for radiology, to integrate the CureMetrix advanced AI diagnostics solution into Nanox’s planned cloud-based software platform, the Nanox.CLOUD.

Nanox is working to expand the range of medical imaging services it intends to provide to improve the accessibility and affordability of early-detection services. The Nanox.CLOUD is designed to provide an end-to-end medical imaging service, including services such as image repository, radiologist matching, online and offline diagnostics review and annotation, connectivity to diagnostic assistive AI systems, billing and reporting.

The goal of screening exams for breast cancer detection is to identify breast abnormalities as early as possible since the likelihood of survival increases the earlier the cancer is detected. Some of the reasons that breast cancer is missed at initial screening include the high-level of difficulty and complexity in reading mammographic images, the fact that dense breast tissue can obscure anomalies, and the limited number of certified mammographers globally.


Special-Pricing Available on Medical Displays, Patient Monitors, Recorders, Printers, Media, Ultrasound Machines, and Cameras.This includes Top Brands such as SONY, BARCO, NDS, NEC, LG, EDAN, EIZO, ELO, FSN, PANASONIC, MITSUBISHI, OLYMPUS, & WIDE.

Understanding the challenges facing radiologists who read mammograms, CureMetrix has developed AI-based computer-aided diagnostic (CAD) solutions that assist radiologists in detecting cancer earlier.

Almost 2% of screening mammograms in the United States result in a biopsy, and approximately 70% of these biopsies are found to be benign (Taplin, 2010). Approximately $4 billion is spent annually in the U.S. on mammography false positives, breast cancer overdiagnosis, invasive breast cancer and ductal carcinoma (Ong, 2015). However, mammography remains the only early detection screening method shown in randomized clinical trials to decrease breast cancer mortality.

CureMetrix aims to leverage its proprietary algorithm to help reduce unnecessary biopsies. In a recent study of biopsy benign cases, CureMetrix’s cmAssist™ software was able to correctly classify 70% of the biopsies as benign. As a result, CureMetrix’s AI CAD could potentially reduce unnecessary biopsies and therefore improve cost efficiencies. In addition, studies have shown that false-positive findings on screening mammography could cause long-term psychosocial harm to patients (Brodersen, 2013). As a result, CureMetrix’s AI CAD could also help alleviate patient anxiety about breast cancer screening.

You Must Be Logged In To Post A Comment